Through targeted T cell depletion experiments, we established that CD8<sup>+</sup> T cells are indispensable for the vaccine's anti-tumor activity, whereas CD4<sup>+</sup> T cell depletion had no significant impact on therapeutic outcomes. This evidence concerns the gene CD4 and neoplasm.